Role of endogenous adenine in kidney failure and mortality with diabetes

3	Kumar	Sharma, M.D. ^{1,2*} , Guanshi Zhang, Ph.D. ^{1,2} , Jens Hansen, M.D. ³ , Petter Bjornstad, M.D. ⁴ , Hak Joo Lee,
4	Ph.D. ^{1,2}	Rajasree Menon, Ph.D. ⁵ , Leila Hejazi, Ph.D. ^{1,6} , Jian-Jun Liu, MBBS ⁷ , Anthony Franzone, B.S. ¹ , Helen C.
5	Looker,	MBBS ⁸ , Byeong Yeob Choi, Ph.D. ^{1,9} , Roman Fernandez, M.S. ⁹ , Manjeri A. Venkatachalam, MBBS ^{1,10} ,
6	Luxcia	Kugathasan, BSc ¹¹ , Vikas S. Sridhar, M.D. ¹¹ , Loki Natarajan, Ph.D. ¹² , Jing Zhang, M.S. ¹² , Varun Sharma,
7	M.Sc. ¹³ ,	Brian Kwan, Ph.D. ¹⁴ , Sushrut Waikar, M.D. ¹⁵ , Jonathan Himmelfarb, M.D. ¹⁶ , Katherine Tuttle, M.D. ¹⁶ , Bryan
8	Kestenb	aum, M.D. ¹⁶ , Tobias Fuhrer, Ph.D. ¹⁷ , Harold Feldman, M.D. ¹⁸ , Ian H. de Boer, M.D. ¹⁶ , Fabio C. Tucci,
9	Ph.D. ¹⁹ ,	John Sedor, M.D. ²⁰ , Hiddo Lambers Heerspink, Ph.D. ^{21,22} , Jennifer Schaub, M.D. ⁵ , Edgar Otto, Ph.D. ⁵ ,
10	Jeffrey	B. Hodgin, M.D. ⁵ , Matthias Kretzler, M.D. ⁵ , Christopher Anderton, Ph.D. ^{1,23} , Theodore Alexandrov, Ph.D. ²⁴ ,
11	David C	herney, M.D. ¹¹ , Su Chi Lim, MBBS ^{7,25,26,27} , Robert G. Nelson M.D. ⁸ , Jonathan Gelfond, M.D. ^{1,9} , Ravi Iyengar,
12	Ph.D. ³ ;	for the Kidney Precision Medicine Project
13	1.	Center for Precision Medicine, The University of Texas Health San Antonio, TX
14	2.	Division of Nephrology, Department of Medicine, The University of Texas Health San Antonio, TX, USA
15	3.	Department of Pharmacological Sciences and Institute for Systems Biomedicine, Icahn School of Medicine
16		at Mount Sinai, New York, NY, USA
17	4.	Division of Nephrology, Department of Medicine and Section of Endocrinology, Department of Pediatrics,
18		University of Colorado Anschutz Medical Campus, Aurora, CO, USA
19	5.	Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
20	6.	SygnaMap, Inc., San Antonio, TX
21	7.	Clinical Research Unit, Khoo Teck Puat Hospital, Singapore
22	8.	Chronic Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix,
23		AZ
24	9.	Department of Population Health Sciences, University of Texas Health San Antonio, 7703 Floyd Curl Drive,
25		San Antonio, TX, 78229, USA
26	10.	Department of Pathology, University of Texas Health San Antonio, TX, USA

27	11.	Department of Medicine, Division of Nephrology, University Health Network, Toronto, Ontario, Canada.
28		Department of Physiology, University of Toronto, Toronto, Ontario, Canada; Cardiovascular Sciences
29		Collaborative Specialization, University of Toronto, Toronto, Canada
30	12.	Department of Family Medicine and Public Health, Herbert Werthein School of Public Health, University of
31		California-San Diego, La Jolla, California. University of California-San Diego Moores Cancer Center,
32		University of California-San Diego, La Jolla, California
33	13.	Center for Molecular Medicine, Vienna, Austria
34	14.	Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles,
35		California
36	15.	Division of Nephrology, Department of Medicine, Boston University, Boston, MA
37	16.	Department of Medicine, University of Washington, Seattle, WA, USA, Division of Nephrology, Department
38		of Medicine, Kidney Research Institute, University of Washington, Seattle, Washington, USA
39	17.	Institute of Molecular Systems Biology, ETH Zurich, 8093, Zurich, Switzerland
40	18.	Center for Clinical Epidemiology and Biostistics, Perelman School of Medicine at the University of
41		Pennsylvania, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at
42		the University of Pennsylvania
43	19.	Epigen Biosciences, Inc., San Diego, California, USA
44	20.	Cleveland Clinic, Cleveland, Ohio
45	21.	Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, the
46		Netherlands
47	22.	The George Institute for Global Health, Sydney, Australia
48	23.	Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, WA, USA
49	24.	Structural and Computational Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany
50	25.	Diabetes Center, Admiralty Medical Center, Khoo Teck Puat Hospital, Singapore
51	26.	Saw Swee Hock School of Public Health, National University of Singapore, Singapore
52	27.	Lee Kong Chian School of Medicine, Nayang Technological University, Singapore
53		

54 *Corresponding Author: Kumar Sharma, MD (Email: <u>sharmak3@uthscsa.edu</u>; Tel: 210-567-4700)

55 Abstract

56 Diabetic kidney disease (DKD) can lead to end-stage kidney disease (ESKD) and mortality, however, few mechanistic 57 biomarkers are available for high risk patients, especially those without macroalbuminuria. Urine from participants 58 with diabetes from Chronic Renal Insufficiency Cohort (CRIC), Singapore Study of Macro-Angiopathy and Reactivity 59 in Type 2 Diabetes (SMART2D), and the Pima Indian Study determined if urine adenine/creatinine ratio (UAdCR) 60 could be a mechanistic biomarker for ESKD. ESKD and mortality were associated with the highest UAdCR tertile in 61 CRIC (HR 1.57, 1.18, 2.10) and SMART2D (HR 1.77, 1.00, 3.12). ESKD was associated with the highest UAdCR 62 tertile in patients without macroalbuminuria in CRIC (HR 2.36, 1.26, 4.39), SMART2D (HR 2.39, 1.08, 5.29), and 63 Pima Indian study (HR 4.57, CI 1.37-13.34). Empagliflozin lowered UAdCR in non-macroalbuminuric participants. 64 Spatial metabolomics localized adenine to kidney pathology and transcriptomics identified ribonucleoprotein 65 biogenesis as a top pathway in proximal tubules of patients without macroalbuminuria, implicating mammalian target 66 of rapamycin (mTOR). Adenine stimulated matrix in tubular cells via mTOR and stimulated mTOR in mouse kidneys. 67 A specific inhibitor of adenine production was found to reduce kidney hypertrophy and kidney injury in diabetic mice. 68 We propose that endogenous adenine may be a causative factor in DKD.

69

70 Introduction

71 Progression to organ failure is marked by fibrosis and loss of architecture in solid organs, such as the kidney. In almost 72 all progressive chronic kidney diseases (CKD) the features that are most consistently associated with functional loss 73 of the glomerular filtration rate (GFR) are the degree of glomerulosclerosis, tubulointerstial fibrosis, vascular injury, 74 and proteinuria (1-4). However, many patients who eventually develop end-stage kidney disease (ESKD) are non-75 proteinuric at the time impaired GFR is recognized. Non-proteinuria is defined as urine albumin-to-creatinine ratio 76 (ACR) < 300 mg/creatinine or urine albumin excretion < 300mg/day (5). As non-proteinuric or non-macroalbuminuric 77 DKD accounts for >40% of prevalent ESKD in patients with type 2 diabetes (5-7) and 75% of prevalent CKD (GFR 78 <60 mL/min/1.73m²) (8) identifying the patients at risk for progression in early stages of disease is an important step 79 to improve clinical outcomes. This is especially relevant as the armamentarium of therapies for DKD to mitigate 80 kidney disease progression has rapidly expanded (9-11).

Establishing novel biomarkers that predict progression and represent biologically relevant pathways in DKD
 could improve the care of patients with diabetes. To identify novel biomarkers, we recently performed an untargeted

urine metabolomics study in patients with type 2 diabetes (T2D) and impaired eGFR from the Chronic Renal Insufficiency Cohort (CRIC) study (12) and identified 15 candidate metabolites associated with ESKD. A targeted assay validated 13 of these metabolites, one of which was adenine. As exogenous adenine has been found to cause kidney failure in mice, rats, and dogs (13-15), we evaluated whether endogenous adenine could play a role in progression of kidney disease in patients with diabetes.

88

89 **Results**

90 Urine adenine/creatinine ratio predicts kidney failure and all cause mortality in the CRIC and SMART2D cohorts. 91 The baseline clinical characteristics of the participants with diabetes from CRIC and SMART2D are shown in Table 92 1. Of the 904 subjects evaluated from CRIC, 558 had either normoalbuminuria or microalbuminuria, 341 had 93 macroalbuminuria, and 5 had no data for 24h albumin. The mean eGFR was 40 mL/min/1.73m². The top tertile of 94 baseline urine adenine/creatinine ratio (UAdCR) was found to identify the participants with diabetes who were at high 95 risk for ESKD and all cause mortality (adjusted HR 1.57, 95% CI 1.18, 2.10, as compared to the lowest tertile) (Figure 96 1A) and a similar significant relationship was found using UAdCR as a continuous variable (Table 2). The value of 97 the top tertile of UAdCR to identify patients with diabetes at high risk for ESKD and all cause mortality was confirmed 98 in participants from SMART2D who had reduced eGFR and normoalbuminuria or microalbuminuria (adjusted HR 99 1.77, 95% CI 1.00, 3.12) (Figure 1B, Table 2, datasets combined in Supplementary Figure 2A).

100 UAdCR predicts kidney failure in the non-macroalbuminuric Pima, CRIC, and SMART2D cohorts and 101 empagliflozin reduces UAdCR. The UAdCR was also evaluated in early-stage disease (measured GFR>90 102 $mL/min/1.73m^2$) in a Pima Indian cohort with >20 year follow up (Table 1). As the majority of the participants in the 103 Pima Indian cohort had non-macroalbuminuria (n=42 of the 54 participants), the association of UAdCR with 104 longitudinal progression to ESKD is presented in this non-macroalbuminuric cohort. ESKD was associated with the 105 top UAdCR tertile (HR 4.57, CI 1.37-13.34) (Supplementary Table 1). UAdCR was also measured from 2 untimed 106 spot urine samples obtained 1 year apart and found to be consistent across the individual paired samples (r=0.665, 107 p < 0.0001) (Supplementary Figure 3). Similar relationships to predict ESKD was found in the non-macroalbuminuric 108 participants in CRIC (adjusted HR 2.36, 95% CI 1.26, 4.39) and SMART2D (adjusted HR 2.39, 95% CI 1.08, 5.29) 109 (Figure 2A, 2B, Supplementary Table 2, combined datasets in Supplementary Figure 2B). Of note, there were no 110 significant correlations of UAdCR with the UACR or eGFR in the non-macroalbuminuric subjects from CRIC or

SMART2D (Supplementary Table 3). Of the CRIC subjects with macroalbuminuria, there were modest associations
between the top tertile of UAdCR and ESKD (HR 1.10, CI 0.75, 1.60) and mortality (HR 1.33, CI 0.59, 3.01).

To determine if UAdCR could be modified in non-macroalbuminuric participants with normal or elevated measured GFR by glycemia or a therapeutic intervention with an SGLT2 inhibitor, the UAdCR was measured during euglycemia or hyperglycemia before and after empagliflozin in patients with T1D (clinical characteristics described in Supplementary Table 4). Acute hyperglycemia did not alter UAdCR levels (Supplementary Figure 4), however empagliflozin significantly lowered UAdCR by 36.4% (Figure 2C).

118 Adenine is localized to regions of kidney fibrosis and is increased in patients with diabetes. A spatial 119 metabolomics platform was developed to annotate small molecules (<700 Da) and performed on kidney biopsies from 120 healthy controls and in patients with diabetes (clinical characteristics in Supplementary Table 4). Adenine was present 121 at low intensity in normal glomeruli and blood vessels in the healthy control kidney (Figure 3A) and enhanced in 122 regions of arteriolosclerosis, tubulointerstial fibrosis and early glomerulosclerosis in the diabetic kidney (Figure 3B). 123 There was an overall increase in adenine in the whole section of kidney biopsies from participants with diabetes as 124 compared to healthy controls (Figure 3C). The spatial adenine values in rat kidney sections were found to correlate 125 well with the UAdCR in a ZDF diabetic model (r=0.73, p<0.001, Supplementary Table 5).

126 Single cell transcriptomics identify ribonucleoprotein biogenesis as a dominant pathway in non-127 macroalbuminuric DKD. As adenine was prominent in regions of tubular pathology in the diabetic kidney and 128 empagliflozin treatment lowered the UAdCR in patients, the proximal tubular cells were considered to be a target cell 129 type affected by adenine. Single cell transcriptomics from proximal tubular cells were studied in DKD patients from 130 the KPMP study (n=28) and an unbiased pathway analysis was performed based on differentially regulated genes. The 131 top pathway identified was the ribosomal nucleoprotein biogenesis pathway in patients without macroalbuminuria and 132 low eGFR (Figure 4A, B). In addition, small and large ribosomal subunit organization pathways were also upregulated 133 in these patients. Replication of these results from KPMP was found in the CROCODILE study in diabetic patients 134 without macroabuminuria and normal GFR (Figure 4C). As ribonucleoprotein biogenesis, and small and large 135 ribosomal subunit organization is closely linked to activity of mammalian target of rapamycin (mTOR) (16) and 136 adenine has been found to stimulate mTOR (17), this pathway was evaluated to mediate adenine-induced effects on 137 proximal tubular cells.

138 Mechanism of adenine induced matrix production is via the mTOR pathway and adenine increases KIM1 and 139 sTNFR1 in mice. To determine whether adenine could be in the causative pathway for tissue fibrosis, adenine was 140 added to mouse and human proximal tubular cells. There was a robust and early stimulation of fibronectin by adenine 141 (Figure 4D, Supplementary Figure 5A). In addition, adenine stimulated mTOR activity as demonstrated by enhanced 142 phosphorylation of S6 kinase (Figure 4E, Supplementary Figure 5B). Inhibition of mTORC1 with rapamycin blocked 143 adenine-induced production of fibronectin (Figure 4E, 4F). Exposure of adenine to normal mice stimulated blood and 144 kidney levels of soluble tumor necrosis factor receptor 1 (sTNFR1) and kidney injury molecule-1 (KIM1), kidney 145 hypertrophy, kidney mTOR activity, and kidney matrix production (Figures 4 G-K; Supplementary Figure 6). 146 Endogenous adenine contributes to diabetic kidney disease in db/db mice. To determine whether endogenous

adenine plays a role in progression of diabetic kidney disease, methylthio-DADMe-Immucillin-A (MTDIA) a small
molecule specific inhibitor of methylthioadenosine phosphorylase (MTAP) was administered to db/db mice, a model
of obese type 2 diabetes. MTAP converts methylthioadenosine to adenine and is responsible for approximately 80%
of adenine production in mammalian cells (18). MTDIA was well tolerated and did not affect food intake, water intake,
blood glucose levels or body weight (Supplementary Table 6). MTDIA significantly reduced kidney adenine in db/db
mice (Figure 5A) but not other metabolites linked to progression of kidney disease (Supplementary Table 7) (19).
MTDIA significantly reduced serum cystatin C, kidney hypertrophy, kidney KIM1, and partially reduced urine ACR,

serum creatinine, urine KIM1, kidney matrix proteins and mTOR activity in db/db mice (Figure 5 B-I).

155

156 Discussion

157 The results from the present study demonstrate a role for endogenous adenine in kidney disease progression in the 158 context of DKD. Urine levels of the AdCR identified patients with diabetes at high risk of kidney failure and all cause 159 mortality at all levels of albuminuria in the CRIC study and verified in a cohort study from Singapore. The UAdCR 160 can also identify patients who will develop ESKD even in the setting of normal or elevated GFR without 161 macroalbuminuria across ethnicities. Spatial metabolomics localized adenine to regions of vascular, tubular, and 162 glomerular pathology in patients with diabetes who have normoalbuminuria and GFR. Adenine appears to be in the 163 causal pathway of kidney fibrosis as adenine was demonstrated to stimulate matrix molecules in proximal tubular cells 164 via mTOR, was causative of kidney matrix production in mice and inhibiting adenine production was protective in 165 diabetic mice.

166 Biomarkers in the causal pathway have not previously been identified for kidney disease progression in non-167 macroalbuminuric patients with diabetes. Microalbuminuria is clearly a risk factor for kidney disease progression, 168 however as microalbuminuria can revert to normoalbuminuria (20) the dependence upon microalbuminuria alone may 169 not provide reliable prognostication for event rates of GFR decline or kidney failure. Non-invasive omics approaches 170 using plasma and urine have identified promising candidate biomarkers (21-23), however, demonstration of a 171 contributory role of these biomarkers to the disease process has been difficult to establish (24). In the present study, 172 integration of spatial metabolomics and single cell transcriptomics of human kidney biopsies converged on adenine 173 and the mTOR pathway as highly relevant to DKD progression. The link with adenine and pathologic features was 174 suggested by spatial metabolomics as adenine could be localized adjacent to atrophic tubules, in regions of 175 arteriosclerotic blood vessels and glomerulosclerosis. The spatial localization implicated adenine to potentially be an 176 endogenous pro-fibrotic factor.

177 Adenine is known to cause kidney pathology as an exogenous toxin in mouse (25) and rat models (14) of CKD, 178 and possibly as an endogenous toxin in humans (26). The pathology of adenine-induced kidney disease includes 179 glomerulosclerosis, tubular atrophy, interstitial fibrosis, and inflammatory cell infiltration (27, 28). The mechanism 180 of adenine induced kidney disease has not been established although it has been postulated that conversion of adenine 181 to 2-8 dihydroxyadenine (26) is a driver of CKD in patients with mutations of adenine phosphoribosyltransferase 182 (APRT), the major enzyme that metabolizes adenine to AMP. However, CKD patients with APRT mutations are rare. 183 Adenine itself is likely an endogenous tubular toxin based on the spatial metabolomic analysis and our finding that 184 high urine adenine identifies patients at high risk of ESKD. Adenine exposure enhances tubular cell matrix production 185 via the mTOR pathway and a prior study found that adenine is a potent stimulus for mTOR (17). Several published 186 studies in mice and rats have also found that inhibiting mTOR protects against adenine-induced kidney disease (29-187 31). The mTOR pathway is likely relevant to human DKD as a recent study found stimulation of mTOR activity in 188 kidney biopsies from patients with DKD (32) and our study with kidney biopsies from KPMP and CROCODILE 189 demonstrate that a number of outputs of mTOR are elevated in DKD. This includes pathways involved in bioenergetics 190 and pathways related to stimulation of extracellular matrix molecules. Further, adenine can increase the levels of 191 KIM1 and sTNFR1 demonstrating that adenine is likely an initiator of downstream injury and inflammatory markers. 192 Endogenous adenine production was blocked with a specific small molecule inhibitor of MTAP (MTDIA) and found 193 to protect against diabetic renal hypertrophy, elevation of kidney KIM1 and was protective of decline in kidney

194 function, as measured by serum cystatin C. It is possible that chronic MTAP inhibition with MTDIA could be 195 developed as a safe therapeutic as a prior study found that MTDIA extended lifespan in mice with colon cancer and 196 was provided for 294 days without evidence of toxicity (33). The role of adenine to accentuate mortality is not clear

197 although it is possible that adenine could be directly toxic to vascular cells.

198 The measure of UAdCR was closely associated with DKD progression in the non-macroalbuminuric diabetic

199 Pima Indian, CRIC, and SMART2D cohorts. As non-macroalbuminuric DKD leads to ESKD in many patients with

200 CKD and diabetes (7, 8, 34), the new UAdCR biomarker could be of clinical value to identify those patients likely to

201 progress. Further, the benefit of SGLT2 inhibitors may be due in part to reduce adenine levels as our study documented

that short term use of empagliflozin significantly attenuated the UAdCR.

Strengths of our study included multiple analysis of several independent cohorts across different ages, ethnicities and stages of DKD. Additional strengths include application of spatial metabolomics and single cell transcriptomics to identify a pathway linking adenine to mTOR in human kidney disease pathology and progression. Limitations of our study was that the role of adenine was not demonstrated in type 1 DKD and other causes of CKD.

In conclusion, urine samples from independent well characterized cohorts of patients with diabetes identified the UAdCR as a robust predictor of ESKD and mortality independent of albuminuria and baseline eGFR, and spatial metabolomic and single cell transcriptomic studies from human kidney biopsies identified a potential role for endogenous adenine and the mTOR pathway in DKD. Studies in cells and mice identified a causative role for adenine and a small molecule therapeutic was found to block adenine production and was nephroprotective in a mouse model of type 2 diabetes. Our results thus demonstrate that endogenous adenine could contribute to progressive kidney disease in the context of type 2 diabetes.

214

215 Methods

Clinical Cohorts. Chronic Renal Insufficiency Cohort (CRIC): The parent CRIC Study recruited a racially diverse group aged 21 to 74 years, ~50% with diabetes, with a broad range of kidney function (35). Informed consent was obtained from participants; protocols were approved by Scientific and Data Coordinating Center). The current study analyzed the urine sample at study entry (from baseline 24h urine samples) of 904 CRIC participants with diabetes and eGFR between 20-70 mL/min/1.73 m² who had samples and outcomes data available. Singapore Study of Macro-Angiopathy and microvascular Reactivity in Type 2 Diabetes cohort (SMART2D): SMART2D is an ongoing

222 prospective cohort study of Southeast Asian T2D participants recruited between 2011-2014 (36). Fasting spot urine 223 samples were collected at baseline and stored at -80°C. To validate findings from the CRIC cohort, 309 participants 224 with baseline eGFR 20-70 mL/min/ $1.73m^2$ and urine ACR < 300 µg/mg were evaluated. All participants gave written 225 informed consent, and the study was approved by the Singapore National Healthcare Group. Pima Indians with early 226 DKD were enrolled in a randomized clinical trial (37) (ClinicalTrials.gov number, NCT00340678). GFR was 227 measured annually throughout the trial by the urinary clearance of iothalamate. Stored spot urine samples collected 228 for two consecutive years were available from 54 participants and included for analysis. Additionally, urine samples 229 were obtained under controlled euglycemic and hyperglycemic clamp conditions from a previously published clinical 230 study in patients with type 1 diabetes (T1D) without macroalbuminuria (n=42) to evaluate the effects of Empagliflozin 231 (Adjunctive-to-insulin and Renal Mechanistic (ATIRMA), NCT01392560) (38). Euglycemic clamp (4-6 mM glucose) 232 conditions were maintained for approximately 4 hours prior to urine collection. The following day hyperglycemia (9-233 11 mM glucose) was maintained for 4 hours. Urine samples for adenine measurements were performed from samples 234 obtained at the 4-hour time point following euglycemia or hyperglycemia before and after empagliflozin (25 mg/d) 235 treatment for 8 weeks.

236 Urine metabolomics (Zip-Chip Analysis). Urine samples from Pima Indians, CRIC, SMART2D cohorts, and 237 ATIRMA urines were all analyzed using ZipChip (908 Devices, Boston, MA) coupled with mass spectrometry (39). 238 A rapid throughput urine adenine/creatinine assay was developed that showed excellent correlation with the gold 239 standard assay using LC-MS/MS (Supplementary Figure 1). The reportable linear range for urine adenine assay was 240 100 nM to 100 uM, with a limit of detection at 10 nM and coefficient of variation (CV)<10% across the reportable 241 linear range. Metabolite separation was achieved with a microfluidic chip which integrates capillary electrophoresis 242 (CE) with nano-electrospray ionization through a ZipChip interface. Data acquisition was performed with Q-Exactive 243 mass spectrometer (Thermo, San Jose, CA) and Thermo Scientific's software Xcalibur-Quan Browser for data 244 processing. Detailed procedures were previously published (39).

Human kidney biopsies. Human kidney samples were obtained via the Kidney Precision Medicine Project (KPMP; The trial registration number from ClinicalTrials.gov is NCT04334707) and the Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance (CROCODILE) studies (40-42). The KPMP and CROCODILE studies were approved by the Institutional Review Board at Washington University, St. Louis, MO and the University of Colorado, respectively, and written consent was obtained from all patients. Samples were frozen in

250 liquid nitrogen and stored at -80 °C until analysis. Snap frozen sample preparation and sectioning procedures for

251 MALDI-MSI were published at dx.doi.org/10.17504/protocols.io.bcraiv2e.

252 Animal studies. Zucker Diabetic Fatty (ZDF) rat kidney and urine samples were provided by Epigen, Inc. to verify 253 that kidney spatial adenine correlated with the targeted urine adenine assay. C57Bl6J mice, db/m and db/db mice were 254 obtained from Jackson Labs. C57Bl6J mice were administered adenine for 4 weeks in drinking water before sacrificing 255 mice and harvesting tissues and blood samples after IACUC approval at UTHSA. db/m and db/db mice were 256 administereted vehicle or methylthio-DADMe-Immucillin-A (MTDIA) MTAP inhibitor for a period of 8 weeks from 257 week 10 to week 18. Albumin ELISA kit (Cat. #, E101 and E90-134, Bethyl Laboratories Inc.) and creatinine 258 colorimetric kit (catalog ADI-907-030A, Enzo Life SciencesInc.) were used for the urinary ACR. Serum cystatin C 259 was measured by Quantikine ELISA kit (Cat. #, MSCTCO, R&D systems). Plasma creatinine and metabolites in 260 kidney tissue were measured by the ZipChip-mass spectrometry as previously described (19). Urine and kidney KIM-261 1 was measured by ELISA (Cat. #DY1817, R&D System).

262 Mass Spectrometry Imaging (MSI) and Optical Imaging of Kidney Biopsies. A multimodal imaging approach was 263 developed to investigate regional localization of metabolites in kidney sections. Bright-field (BF) and 264 autofluorescence (AF) microscopy outlined glomeruli and tubules, and PAS-H staining revealed regions of pathology 265 in serial sections. Matrix assisted laser desorption/ionization (MALDI)-MSI was performed with a Thermo Scientific 266 Q Exactive HF-X hybrid quadrupole-Orbitrap mass spectrometer (Thermo Scientific) in combination with a novel 267 elevated pressure MALDI/ESI interface (Spectroglyph LLC, Kennewick, WA) (43). Metabolite annotation was 268 performed on METASPACE (44) and the optical image was uploaded to METASPACE and SCiLS Lab for visual 269 overlay of metabolites with optical images to provide an assessment of metabolites associated with normal-appearing 270 pathologic available and features. Detailed procedures for MALDI-MSI are at 271 dx.doi.org/10.17504/protocols.io.bctfiwjn.

272 *Cell culture.* Human kidney proximal tubular (HK-2) cells were purchased from American Type Culture 273 Collection (Manassas, VA) and cultured as previously described (45). Murine kidney proximal tubular epithelial 274 (MCT) cells were cultured as previously described (46). Cells were treated with 20 μ M of adenine for the indicated 275 time points with and without rapamycin (Fisher Scientific). Phosphorylation of S6 kinase, ribosomal protein S6 and 276 expression of fibronectin and type 1 collagen α 2 were analyzed by immunoblotting using antibodies against phosphor-277 Thr389-S6 kinase (Cat. # 9205, Cell Signaling Technology), phosphor-Ser240/244 ribosomal protein S6 (Cat. #, 2215,

278 Cell Signaling Technology), ribosomal protein S6 (Cat. #, 2217, Cell Signaling Technology), MTAP (Cat. #, 62765,

279 Cell Signaling Technology), fibronectin (Cat. #, ab2413, Abcam Plc), type 1 collagen α2 (Cat. #, 14695-1-AP,

280 Proteintech Group Inc), and beta-actin (Cat. #, A2066, Millipore Sigma).

281 Statistical Analysis. A composite kidney endpoint was defined as sustained kidney replacement therapy, 282 progression to GFR or eGFR $< 15 \text{ mL/min}/1.73\text{m}^2$, or >50% GFR or eGFR decline from baseline level. All-cause 283 mortality included death from any cause before reaching ESKD endpoint. Urine adenine was normalized to urine 284 creatinine concentrations and log2 transformed. In the CRIC and SMART2D cohorts, the association of urine 285 adenine levels (tertile) with clinical endpoints was studied by multivariable Cox proportional hazard regression 286 models with adjustment for age, gender, ethnicity/race, body-mass index (BMI), hemoglobin A1c (HbA1c), mean 287 arterial pressure (MAP), baseline eGFR, and urine ACR (natural log-transformed) as covariates. The group with a 288 urine adenine/creatinine ratio in the lowest tertile was used as reference. Due to the limited number of cases in the 289 Pima Indian cohort we only reported univariate Cox proportional hazards analysis for this cohort. To evaluate the 290 pre-treatment and post-treatment effect of empagliflozin on urine adenine in the ATIRMA cohort, we performed a 291 linear regression analysis for repeated measures.

Bioinformatic and systems medicine analysis. Single cell transcriptomics and spatial metabolomics datasets generated from healthy kidney tissue, unaffected tissue in kidney nephrectomy and biopsy samples (KPMP and CROCODILE) were analyzed as recently described (40-42). The top pathway genes and proteins from the top 600 significant genes or proteins from proximal tubular cells were mapped onto pathways for subcellular processes using the MBCO ontology (47).

Study Approval. For the CRIC study, Informed consent was obtained from participants; protocols were approved by IRBs and Scientific and Data Coordinating Center. All participants gave written informed consent, and the study was approved by the Singapore National Healthcare Group. The KPMP and CROCODILE studies were approved by the Institutional Review Board at Washington University, St. Louis, MO and the University of Colorado, respectively, and written consent was obtained from all patients.

302

303 Author Contributions

The first 9 coauthors each made unique and critical contributions to this manuscript, and authorship order was determined after discussion among writing group members. KS, PB, SCL, JJL, RI, RGN, MK, and GZ designed the

study. KS, PB, SCL, DC and RGN acquired funding for the study. GZ, JH, HJL, RM, PB, JJL, HL, LH, PB, LK, VSS
acquired or generated the data. GZ, JH, HJL, JJL, HL, BC, LK and JG analyzed the data. KS, GZ, PB, MK, RGN and
RI wrote the manuscript. KS, PB, MK, SCL, LN, JZ, VS, BK, SW, JH, KT, BK, TF, HF, IB, JS, HDL, JS, RM, EO,
CA, TA, SCL, RGN, JG and RI provided scientific guidance and insights. All authors reviewed, edited, and approved

- the manuscript.
- 311

312 **Conflicts of Interest**

313 K.S. reports serving as consultant for Visterra, Bayer, Sanofi, and receiving research support from Boerhinger-314 Ingelheim. K.S. also reports having equity in a startup company, SygnaMap. P.B. reports serving as a consultant for 315 AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli-Lilly, LG Chemistry, Sanofi, Novo Nordisk, 316 and Horizon Pharma. P.B. also serves on the advisory boards of AstraZeneca, Bayer, Boehringer Ingelheim, Novo 317 Nordisk, and XORTX. K.R.T. reports other support from Eli Lilly; personal fees and other support from Boehringer 318 Ingelheim; personal fees and other support from AstraZeneca; grants, personal fees and other support from Bayer AG; 319 grants, personal fees and other support from Novo Nordisk; grants and other support from Goldfinch Bio; other support 320 from Gilead; and grants from Travere outside the submitted work. R.G.N. and H.C.L. report no conflicts. J.H. reports 321 serving as a consultant for Maze Therapeutics, Chinook Therapeutics, Renalytix AI, and Seattle Genetics. D.C. has 322 received honoraria from Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, AbbVie, 323 Janssen, Bayer, Prometric, BMS, Maze, CSL Behring, and Novo Nordisk. H.L.H. has received honoraria for 324 participation in steering committees from AstraZeneca, Janssen, Eli-Lilly, Gilead, Baver, Chinook, Novartis, and CSL 325 Behring; honoraria for participation in advisory boards from AstraZeneca, Vifor, Novartis, NovoNordisk, and Idorsia; 326 fees for consultancy from AstraZeneca, Travere Pharmaceuticals, Boehringer Ingelheim, and Novo Nordisk; and 327 research grant support from AstraZeneca, Janssen, Boehringer Ingelheim and NovoNordisk. Honoraria are paid to his 328 institution [University Medical Center Groningen].

329

330 Acknowledgments

331 G.Z, L.H., H.J.L, A.F, and K.S. receives salary and research support from NIH (UH3DK114920, 5U2CDK114886,

332 RO1DK110541). L.N., J.Z., B.K. were supported by NIDDK 5R01DK110541. J.J.L. receives research support from

333 Alexandra Health Fund (STAR grant 18203 and 20201). S.C.L. receives research support from Singapore National

334 Medical Research Councile (MOH-000066, 0000714 and OFLCG/001/2017). P.B. receives salary and research 335 support from NIDDK (R01 DK129211, R21 DK129720, K23 DK116720, UC DK114886, and P30 DK116073), JDRF 336 (2-SRA-2019-845-S-B, 3-SRA-2017-424-M-B, 3-SRA-2022-1097-M-B), Boettcher Foundation, American Heart 337 Association (20IPA35260142), Ludeman Family Center for Women's Health Research at the University of Colorado, 338 the Department of Pediatrics, Section of Endocrinology and Barbara Davis Center for Diabetes at University of 339 Colorado School of Medicine. K.R.T. receives salary and research support from the NIDDK, NIMHD, NCATS, and 340 NHLBI (R01MD014712, U2CDK114886, UL1TR002319, U54DK083912, U01DK100846, OT2HL161847, 341 UM1AI109568) and the CDC (75D301-21-P-12254). R.G.N. was supported by the American Diabetes Association 342 (Clinical Science Award 1-08-CR-42) and R.G.N. and H.C.L. were supported by the Intramural Research Program of 343 NIDDK. J.H. and R.I. received salary support from U3CDK114886, R01GM137056, P01HL134605. Funding for the 344 CRIC Study was obtained under a cooperative agreement from National Institute of Diabetes and Digestive and 345 Kidney Diseases (U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, 346 U01DK060963, U01DK060902 and U24DK060990). In addition, this work was supported in part by: the Perelman 347 School of Medicine at the University of Pennsylvania Clinical and Translational Science Award NIH/NCATS 348 UL1TR000003, Johns Hopkins University UL1 TR-000424, University of Maryland GCRC M01 RR-16500, Clinical 349 and Translational Science Collaborative of Cleveland, UL1TR000439 from the National Center for Advancing 350 Translational Sciences (NCATS) component of the National Institutes of Health and NIH roadmap for Medical 351 Research, Michigan Institute for Clinical and Health Research (MICHR) UL1TR000433, University of Illinois at 352 Chicago CTSA UL1RR029879, Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases 353 P20 GM109036, Kaiser Permanente NIH/NCRR UCSF-CTSI UL1 RR-024131, Department of Internal Medicine, 354 University of New Mexico School of Medicine Albuquerque, NM R01DK119199. We acknowledge technical help 355 for animal studies from Richard Montellano, transcriptomics data organization from Fadhl AlAkwaa and Philip 356 McCown, method development from Annapurna Pamreddy and data analysis by Rabiul Islam. D.C. has received 357 operational funding for clinical trials from Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, and 358 Novo Nordisk.

359

360 Appendix

361 The author affiliations are as follows: the Center for Precision Medicine, the University of Texas Health San Antonio, 362 TX, USA (G.Z., A.F., L.H., H.J.L., M.A.V., C.A., J.G., K.S.), the Division of Nephrology, Department of Medicine, 363 the University of Texas Health San Antonio, TX, USA (G.Z., H.J.L., K.S.), the Department of Pharmacological 364 Sciences and Institute for Systems Biomedicine Icahn School of Medicine at Mount Sinai, New York, NY, USA 365 (J.H., R.I.), the Chronic Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, 366 Phoenix, AZ (H.C.L., R.G.N.), the Clinical Research Unit, Khoo Teck Puat Hospital, Singapore (J.J.L., S.C.L., J.G.), 367 the Department of Population Health Sciences, University of Texas Health San Antonio, 7703 Floyd Curl Drive, San 368 Antonio, TX, 78229, USA (R.F.), the SygnaMap, San Antonio, Texas, USA (L.H.), Audie L. Murphy Memorial VA 369 Hospital, South Texas Veterans Health Care System, San Antonio, TX, USA (G.Z., H.J.L., K.S.), the Department of 370 Pathology, University of Texas Health San Antonio, TX, USA (M.A.V.), the Department of Family Medicine and 371 Public Health, Herbert Werthein School of Public Health, University of California-San Diego, La Jolla, California 372 (L.N.), the University of California-San Diego Moores Cancer Center, University of California-San Diego, La Jolla, 373 California (L.N., J.Z.), the Center for Molecular Medicine, Vienna, Austria (V.S.), the Department of Biostatistics, 374 Fielding School of Public Health, University of California, Los Angeles, California (B.K.), the Division of 375 Nephrology, Department of Medicine, Boston University, Boston, MA (S.W.), the Department of Medicine, 376 University of Washington, Seattle, WA, USA and the Division of Nephrology, Department of Medicine, Kidney 377 Research Institute, University of Washington, Seattle, Washington, USA (J.H., K.T., B.K., I.D.B.), the Division of 378 Nephrology, Department of Medicine and Section of Endocrinology, Department of Pediatrics, University of Colorado 379 Anschutz Medical Campus, Aurora, CO, USA (P.B.), the Institute of Molecular Systems Biology, ETH Zurich, 8093, 380 Zurich, Switzerland (T.F.), the Center for Clinical Epidemiology and Biostistics, Perelman School of Medicine at the 381 University of Pennsylvania and the Department of Biostatistics, Epidemiology, and Informatics, Perelman School of 382 Medicine at the University of Pennsylvania (H.F.), the Epigen Biosciences, Inc., San Diego, California, USA (F.C.T.), 383 the Cleveland Clinic, Cleveland, Ohio (J.S.), Department of Clinical Pharmacy and Pharmacology, University of 384 Groningen, University Medical Center Groningen, Groningen, the Netherlands (H.L.H.), The George Institute for 385 Global Health, Sydney, Australia (H.L.H.), the Department of Internal Medicine, University of Michigan, Ann Arbor, 386 Michigan, USA (R.M., E.O., J.H., M.K.), the Environmental Molecular Sciences Laboratory, Pacific Northwest 387 National Laboratory, Richland, WA, USA (C.A.), the Structural and Computational Biology Unit, European 388 Molecular Biology Laboratory, Heidelberg, Germany (T.A.), the Diabetes Center, Admiralty Medical Center,

- 389 Singapore and the Saw Swee Hock School of Public Health, National University of Singapore, Singapore and the Lee
- 390 Kong Chian School of Medicine, Nayang Technological University, Singapore (S.C.L.)

-

-

415 **References**

- 416 1. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. *Am J Kidney Dis.*417 1992;20(1):1-17.
- 418 2. Di Vincenzo A, Bettini S, Russo L, Mazzocut S, Mauer M, and Fioretto P. Renal structure in type 2 diabetes:
- 419 facts and misconceptions. *J Nephrol.* 2020;33(5):901-7.
- 420 3. Mauer SM, Steffes MW, and Brown DM. The kidney in diabetes. *Am J Med.* 1981;70(3):603-12.
- 421 4. Caramori ML, Parks A, and Mauer M. Renal lesions predict progression of diabetic nephropathy in type 1
 422 diabetes. *J Am Soc Nephrol.* 2013;24(7):1175-81.
- 423 5. Yamanouchi M, Furuichi K, Hoshino J, Ubara Y, and Wada T. Nonproteinuric diabetic kidney disease. *Clinical*424 *and experimental nephrology*. 2020;24(7):573-81.
- 425 6. Berhane AM, Weil EJ, Knowler WC, Nelson RG, and Hanson RL. Albuminuria and estimated glomerular
- filtration rate as predictors of diabetic end-stage renal disease and death. *Clin J Am Soc Nephrol*. 2011;6(10):2444-
- 427 51.
- 428 7. Porrini E, Ruggenenti P, Mogensen CE, Barlovic DP, Praga M, Cruzado JM, et al. Non-proteinuric pathways in
 429 loss of renal function in patients with type 2 diabetes. *Lancet Diabetes Endocrinol.* 2015;3(5):382-91.
- 430 8. Pichaiwong W, Homsuwan W, and Leelahavanichkul A. The prevalence of normoalbuminuria and renal
 431 impairment in type 2 diabetes mellitus. *Clin Nephrol.* 2019;92(2):73-80.
- 432 9. Caramori ML, Fioretto P, and Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin
 433 excretion rate sufficient? *Diabetes*. 2000;49(9):1399-408.
- 434 10. Forst T, Mathieu C, Giorgino F, Wheeler DC, Papanas N, Schmieder RE, et al. New strategies to improve clinical
 435 outcomes for diabetic kidney disease. *BMC Med.* 2022;20(1):337.
- 436 11. Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, Kolkhof P, et al. Molecular mechanisms and
 437 therapeutic targets for diabetic kidney disease. *Kidney Int.* 2022;102(2):248-60.
- 438 12. Zhang J, Fuhrer T, Ye H, Kwan B, Montemayor D, Tumova J, et al. High-Throughput Metabolomics and Diabetic
 439 Kidney Disease Progression: Evidence from the Chronic Renal Insufficiency (CRIC) Study. *Am J Nephrol.*440 2022:1-11.
- 441 13. Rahman A, Yamazaki D, Sufiun A, Kitada K, Hitomi H, Nakano D, et al. A novel approach to adenine-induced
- 442 chronic kidney disease associated anemia in rodents. *Plos One.* 2018;13(2):e0192531.

- 443 14. Diwan V, Brown L, and Gobe GC. Adenine-induced chronic kidney disease in rats. *Nephrology (Carlton)*.
 444 2018;23(1):5-11.
- 445 15. Claramunt D, Gil-Pena H, Fuente R, Hernandez-Frias O, and Santos F. Animal models of pediatric chronic kidney
- 446 disease. Is adenine intake an appropriate model? *Nefrologia : publicacion oficial de la Sociedad Espanola*
- 447 *Nefrologia*. 2015;35(6):517-22.
- Schiaffino S, Reggiani C, Akimoto T, and Blaauw B. Molecular Mechanisms of Skeletal Muscle Hypertrophy. J
 Neuromuscul Dis. 2021;8(2):169-83.
- 450 17. Hoxhaj G, Hughes-Hallett J, Timson RC, Ilagan E, Yuan M, Asara JM, et al. The mTORC1 Signaling Network
 451 Senses Changes in Cellular Purine Nucleotide Levels. *Cell Rep.* 2017;21(5):1331-46.
- 452 18. Lubin M, and Lubin A. Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel
 453 strategy. *Plos One.* 2009;4(5):e5735.
- 454 19. Zhang J, Fuhrer T, Ye H, Kwan B, Montemayor D, Tumova J, et al. High-Throughput Metabolomics and Diabetic
 455 Kidney Disease Progression: Evidence from the Chronic Renal Insufficiency (CRIC) Study. *Am J Nephrol.*456 2022;53(2-3):215-25.
- 457 20. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, and Krolewski AS. Regression of
 458 microalbuminuria in type 1 diabetes. *N Engl J Med.* 2003;348(23):2285-93.
- 459 21. Niewczas MA, Pavkov ME, Skupien J, Smiles A, Md Dom ZI, Wilson JM, et al. A signature of circulating
 460 inflammatory proteins and development of end-stage renal disease in diabetes. *Nat Med.* 2019;25(5):805-13.
- 461 22. Tofte N, Lindhardt M, Adamova K, Bakker SJL, Beige J, Beulens JWJ, et al. Early detection of diabetic kidney
- 462 disease by urinary proteomics and subsequent intervention with spironolactone to delay progression
- 463 (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet
- 464 *Diabetes Endocrinol.* 2020;8(4):301-12.
- Sharma K, Karl B, Mathew AV, Gangoiti JA, Wassel CL, Saito R, et al. Metabolomics reveals signature of
 mitochondrial dysfunction in diabetic kidney disease. *J Am Soc Nephrol.* 2013;24(11):1901-12.
- 467 24. Looker HC, Mauer M, and Nelson RG. Role of Kidney Biopsies for Biomarker Discovery in Diabetic Kidney
 468 Disease. *Adv Chronic Kidney Dis.* 2018;25(2):192-201.

- 469 25. de Frutos S, Luengo A, Garcia-Jerez A, Hatem-Vaquero M, Griera M, O'Valle F, et al. Chronic kidney disease
- 470 induced by an adenine rich diet upregulates integrin linked kinase (ILK) and its depletion prevents the disease
 471 progression. *Biochim Biophys Acta Mol Basis Dis*, 2019;1865(6):1284-97.
- 472 26. George SA, Al-Rushaidan S, Francis I, Soonowala D, and Nampoory MRN. 2,8-Dihydroxyadenine Nephropathy
 473 Identified as Cause of End-Stage Renal Disease After Renal Transplant. *Exp Clin Transplant*. 2017;15(5):574-7.
- 474 27. Mo Y, Sun H, Zhang L, Geng W, Wang L, Zou C, et al. Microbiome-Metabolomics Analysis Reveals the
- 475 Protection Mechanism of alpha-Ketoacid on Adenine-Induced Chronic Kidney Disease in Rats. *Front Pharmacol.*476 2021;12:657827.
- 477 28. Saleh MA, Awad AM, Ibrahim TM, and Abu-Elsaad NM. Small-Dose Sunitinib Modulates p53, Bcl-2, STAT3,
- 478 and ERK1/2 Pathways and Protects against Adenine-Induced Nephrotoxicity. *Pharmaceuticals (Basel)*.
 479 2020;13(11).
- 480 29. Wang J, Chai L, Lu Y, Lu H, Liu Y, and Zhang Y. Attenuation of mTOR Signaling Is the Major Response
 481 Element in the Rescue Pathway of Chronic Kidney Disease in Rats. *Neuroimmunomodulation*. 2020;27(1):9-18.
- 30. Nakano T, Watanabe H, Imafuku T, Tokumaru K, Fujita I, Arimura N, et al. Indoxyl Sulfate Contributes to
 mTORC1-Induced Renal Fibrosis via The OAT/NADPH Oxidase/ROS Pathway. *Toxins (Basel)*. 2021;13(12).
- 484 31. Zhao Y, Zhao MM, Cai Y, Zheng MF, Sun WL, Zhang SY, et al. Mammalian target of rapamycin signaling
 485 inhibition ameliorates vascular calcification via Klotho upregulation. *Kidney Int.* 2015;88(4):711-21.
- 486 32. Schaub JA, AlAkwaa FM, McCown PJ, Naik AS, Nair V, Eddy S, et al. SGLT2 inhibitors mitigate kidney tubular
 487 metabolic and mTORC1 perturbations in youth-onset type 2 diabetes. *J Clin Invest.* 2023;133(5).
- 488 33. Firestone RS, Feng M, Basu I, Peregrina K, Augenlicht LH, and Schramm VL. Transition state analogue of MTAP
 489 extends lifespan of APC(Min/+) mice. *Sci Rep.* 2021;11(1):8844.
- 490 34. Liyanage P, Lekamwasam S, Weerarathna TP, and Srikantha D. Prevalence of normoalbuminuric renal
 491 insufficiency and associated clinical factors in adult onset diabetes. *BMC Nephrol.* 2018;19(1):200.
- 492 35. Yaffe K, Ackerson L, Tamura MK, Le Blanc P, Kusek JW, Sehgal AR, et al. Chronic Kidney Disease and
- 493 Cognitive Function in Older Adults: Findings from the Chronic Renal Insufficiency Cohort Cognitive Study.
- 494 *Journal of the American Geriatrics Society*. 2010;58(2):338-45.

- 495 36. Pek SL, Tavintharan S, Wang X, Lim SC, Woon K, Yeoh LY, et al. Elevation of a novel angiogenic factor,
- 496 leucine-rich-alpha2-glycoprotein (LRG1), is associated with arterial stiffness, endothelial dysfunction, and 497
- peripheral arterial disease in patients with type 2 diabetes. J Clin Endocrinol Metab. 2015;100(4):1586-93.
- 498 37. Weil EJ, Fufaa G, Jones LI, Lovato T, Lemley KV, Hanson RL, et al. Effect of losartan on prevention and
- 499 progression of early diabetic nephropathy in American Indians with type 2 diabetes. Diabetes. 2013;62(9):3224-
- 500 31.
- 501 38. Škrtić M, Yang GK, Perkins BA, Soleymanlou N, Lytvyn Y, von Eynatten M, et al. Characterisation of glomerular 502 haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. 503 Diabetologia. 2014;57(12):2599-602.
- 504 39. Liu H, Sridhar VS, Montemayor D, Lovblom LE, Lytvyn Y, Ye H, et al. Changes in plasma and urine metabolites 505 associated with empagliflozin in patients with type 1 diabetes. Diabetes, obesity & metabolism. 506 2021;23(11):2466-75.
- 507 40. Lake BB, Chen S, Hoshi M, Plongthongkum N, Salamon D, Knoten A, et al. A single-nucleus RNA-sequencing 508 pipeline to decipher the molecular anatomy and pathophysiology of human kidneys. Nat Commun. 509 2019;10(1):2832.
- 510 41. Menon R, Otto EA, Hoover P, Eddy S, Mariani L, Godfrey B, et al. Single cell transcriptomics identifies focal 511 segmental glomerulosclerosis remission endothelial biomarker. JCI Insight. 2020;5(6).
- 512 42. Hansen J, Sealfon R, Menon R, Eadon MT, Lake BB, Steck B, et al. A reference tissue atlas for the human kidney. 513 Science advances. 2022;8(23):eabn4965.
- 514 43. Belov ME, Ellis SR, Dilillo M, Paine MRL, Danielson WF, Anderson GA, et al. Design and Performance of a
- 515 Novel Interface for Combined Matrix-Assisted Laser Desorption Ionization at Elevated Pressure and Electrospray
- 516 Ionization with Orbitrap Mass Spectrometry. Anal Chem. 2017;89(14):7493-501.
- 517 44. Palmer A, Phapale P, Chernyavsky I, Lavigne R, Fay D, Tarasov A, et al. FDR-controlled metabolite annotation 518 for high-resolution imaging mass spectrometry. *Nature methods*. 2017;14(1):57-60.
- 519 45. Yang L, Besschetnova TY, Brooks CR, Shah JV, and Bonventre JV. Epithelial cell cycle arrest in G2/M mediates 520 kidney fibrosis after injury. Nat Med. 2010;16(5):535-43, 1p following 143.

- 521 46. Lee HJ, Lee DY, Mariappan MM, Feliers D, Ghosh-Choudhury G, Abboud HE, et al. Hydrogen sulfide inhibits
- 522 high glucose-induced NADPH oxidase 4 expression and matrix increase by recruiting inducible nitric oxide
- 523 synthase in kidney proximal tubular epithelial cells. *J Biol Chem.* 2017;292(14):5665-75.
- 524 47. Hansen J, Meretzky D, Woldesenbet S, Stolovitzky G, and Iyengar R. A flexible ontology for inference of
- 525 emergent whole cell function from relationships between subcellular processes. *Sci Rep.* 2017;7(1):17689.
- 526

528 Table 1. Baseline characteristics of patients with diabetes in the Pima American Indians, CRIC and SMART2D

529 studies.

	Pima cohort (N=54)	CRIC cohort (N=904)	SMART2D cohort (N=309)		
Characteristics	Mean ± SD/N (%)	Mean ± SD/N (%)	Mean ± SD/N (%)		
Index age (years)	45.1 ± 9.6	60 ± 9.4	64.5 ± 9.6		
Sex					
Male	13 (24%)	515 (57%)	176 (57%)		
Female	41 (76%)	390 (43%)	133 (43%)		
		Black: 376 (41%)			
Ethnicity (%)	American Indian: 54 (100%)	Hispanic: 141 (16%)	Chinese: 163 (53%)		
		Other: 37 (4%)	Malay: 71 (23%)		
		White: 350 (39%)	Asian Indian: 75 (24%)		
Current smoker					
Yes		510 (56%)	20 (7%)		
No		391 (43%)	289 (93%)		
Body mass index (kg/m ²)	35.4 ± 7.1	34 ± 7.8	27.7 ± 5.3		
HbA1c (%)	9.6 ± 2	7.6 ± 1.6	7.6 ± 1.3		
Mean artery pressure (mmHg)	93.2 ± 10	90 ± 13	98 ± 11		
eGFR* mL/min/1.73m ²)	139 ± 49	$40\pm~12$	53 ± 13		
ACR** (median (IQR), mg/g)	40 (15 -164)	116 (16 - 756)	27 (11- 87)		
ACR category (N,%)***					
< 30 mg/g	26 (48%)	298 (33%)	162 (52%)		
30-300 mg/g	16 (30%)	260 (28%)	147 (48%)		
>300 mg/g	12 (22%)	341 (39%)			

BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; UACR, urine albuminto-creatinine ratio; *data for Pima cohort is measured GFR in ml/min; **Continuous ACR is summarized using
median (IQR, interquartile range) because of its skewed distribution. ***data for CRIC cohort is based on 24h urine
albumin or albumin/creatinine values. For ACR category and all other continuous variables are summarized using
mean ± SD.

542 **Table 2.** Association of baseline urine adenine/creatinine ratio (UAdCR) with risk for progression to ESKD and all-

543 cause mortality in CRIC and SMART2D participants with type 2 diabetes with 7 years follow up.

544

	CRIC cohort (N=889)	SMART2D cohor	t (N=309)
Adenine/Creatinine ratio	HR (95% CI)	p value	HR (95% CI)	p value
1-SD increment	1.15 (1.03-1.28)	0.010	1.48 (1.15-1.90)	0.003
Tertile 2 vs tertile 1	1.59 (1.21-2.09)	< 0.001	0.81 (0.44-1.50)	0.502
Tertile 3 vs tertile 1	1.57 (1.18-2.10)	0.002	1.77 (1.00-3.12)	0.048

546	Multivariate Cox proportional hazard regression models were adjusted for baseline age, sex, ethnicity, body mass
547	index, mean arterial pressure, hemoglobin A1c, eGFR and natural-log transformed urine albumin/creatinine ratio.
548	UAdCR was modelled as both continuous variable (1-SD increment in log2-transformed adenine/creatinine ratio) and
549	categorical variable (low tertile as reference). There were 15 subjects in CRIC with missing values for the clinical co-
550	variates.
551	
552	
553	
554	
555	
556	
557	
558	
559	
560	
561	
562	
563	
564	
565	
566	





Figure 1. High urine adenine/creatinine (UAdCR) levels identify patients with diabetes who are at high risk of end stage kidney disease (ESKD) and mortality. Participants with diabetes in the Chronic Renal Insufficiency Cohort (CRIC) cohort (n=904) had UAdCR measured within 1 year of enrollment and followed for 10 years. The participants in the top tertile had the highest risk of ESKD and all cause mortality (A). Participants from the Singapore Study of Macro-Angiopathy and microvascular Reactivity in Type 2 Diabetes (SMART2D) study (n=309) had UAdCR measurements at the time of enrollment and were followed for 7 years. The participants in the top tertile for UAdCR had the highest risk for ESKD and all-cause mortality.

- 577
- 578
- 579
- 580
- 581
- 582

- 584
- 585



587 Figure 2. High urine adenine/creatinine (UAdCR) tertile identifies end stage kidney disease (ESKD) outcome 588 in non-macroalbuminuric patients with diabetes and empagliflozin reduced urine adenine/creatinine ratio. The 589 participants with the top UAdCR tertile had a significant increase in risk of ESKD from CRIC (n=551) (A) and 590 SMART2D (n=309) (B) studies. Patients with T1 diabetes underwent treatment with empagliflozin for 8 weeks which 591 reduced UAdCR levels (n=40 patients) (C).



607 Figure 3. Spatial metabolomics identifies adenine in regions of pathology in non-macroalbuminuric patients 608 with diabetes. Adenine was localized to regions of normal glomeruli and vessels in the normal kidney (A). In a 609 diabetic kidney, adenine is diffusely increased across the tissue section and prominent in regions of sclerotic blood 610 vessels, glomeruli with mild sclerosis and regions of atrophic tubules and interstitial inflammation (B). Quantitative 611 assessment across healthy controls (n=5 from Control of Renal Oxygen Consumption, Mitochondrial Dysfunction and 612 Insulin Resistance (CROCODILE) study) and diabetic samples (n=8 T1D from CROCODILE and n=8 T2D (2 from 613 CROCODILE and 6 from Kidney Precision Medicine Project (KPMP)) demonstrates a statistically significant 614 increase of adenine in kidney tissue sections (C).



616 Figure 4. Molecular pathways and events implicating ribonucleoprotein biogenesis and mammalian target of 617 rapamycin (mTOR) pathway with adenine in diabetic kidney disease (DKD): Protein synthesis 618 (Ribonucleoprotein (RNP) biogenesis) pathway increased in proximal tubule cells of DKD patients without 619 proteinuria (A) Single cell- transcriptomic data obtained from DKD kidney biopsies for the Kidney Precision Medicine 620 Project (KPMP) was analyzed for differentially expressed genes in proximal tubule (PT) of each DKD patient versus 621 healthy reference tissue. Upregulated genes with an adjusted p-value ≤ 0.01 and ranked among the top 600 significant 622 DEGs were subjected to pathway enrichment analysis using the Molecular Biology of the Cell Ontology (MBCO). 623 Ranking for the RNP biogenesis pathway (a Level 2 pathway canonically regulated by the mTOR pathway) is shown 624 for 28 individual patients. Vertical dashed line indicates p value ≤ 0.01 for pathway ranking (B) Up to top five, five, 625 ten and five level-1 (dark red), level-2 (red), level-3 (blue) and level-4 (green) pathways using MBCO are shown for 626 patient #1 (p-value ≤ 0.01). See blue lines from A to B. Single cell transcriptomic data from T2D patients (N=6) with 627 low albuminuria compared to cohort specific healthy samples was analyzed to identify upregulated pathways in PT 628 cells (C). Note that the RNP biogenesis pathway is the top ranked Level-2 pathway in both independent studies. Cell

629	culture studies in mouse proximal tubular cells demonstrated an increase in fibronectin (D), phospho-S6 kinase and
630	mediation of fibronectin (FN) upregulation is blocked by rapamycin (E, F), indicating mTOR mediates adenine effect.
631	Adenine administration to mice increases serum soluble tumor necrosis factor-1 (sTNFR1) (G), plasma kidney injury
632	marker-1 (KIM-1) (H), stimulates kidney (I) and matrix molecules in the kidney (J, K) (n=12 in control group and
633	n=7 in adenine treated group, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).
634	
635	
636	
637	
638	
639	
640	
641	
642	
643	
644	
645	
646	
647	
648	
649	
650	
651	
652	
653	
654	
655	
656	







669 Supplementary Figures and Tables

- 670 Supplementary Table 1. Hazard Ratios of ESKD or >50% decline in GFR incidence between tertiles of urine
- 671 adenine/creatinine ratio (UAdCR) in Pima cohort without macroalbuminuria.
- 672

			Continuou	15	Т	2 vs T1			T3 vs T1	
Pima American Indians	N	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value
No macroalbuminuria	42	1.89	1.18-3.03	0.008	1.66	0.54-5.09	0.37	4.57	1.57-13.44	0.006
HR = hazard ratio; CI =	confic	lence in	nterval; No	macroalbu	uminuri	ia (ACR <3	00 mg/g).	T1 = lo	west tertile	ofUAdCR
T2=middle tertile of UA	dCR	and T3	= highest t	ertile of U	JAdCR	. For the co	ntinuous 1	neasure	e of UAdCR	, HR is pe
standard deviation in na	tural l	og-tran	sformed U	AdCR.						

694	Supplementary	Table 2.	Association	of baseline	urine ad	enine/crea	atinine ratio	o (UAdCR)	with risk f	or progression	ı to

695	ESKD in CRIC and SMART2D participants with non-macroalbuminuria and type 2 diabetes with 7 year follow up.

	CRIC cohort (N=551)	SMART2D cohort (N=30			
Adenine/Creatinine ratio	HR (95% CI)	p value	HR (95% CI)	p value		
1-SD increment	1.37 (1.08-1.73)	0.011	1.70 (1.21-2.39)	0.002		
Tertile 2 vs tertile 1	1.96 (1.06-3.60)	0.031	0.91 (0.37-2.28)	0.848		
Tertile 3 vs tertile 1	2.36 (1.26-4.39)	0.006	2.39 (1.08-5.29)	0.032		

697	Multivariate Cox proportional hazard regression models were adjusted for baseline age, sex, ethnicity, body mass
698	index, mean arterial pressure, hemoglobin A1c, eGFR and natural-log transformed urine albumin/creatinine ratio.
699	UAdCR was modelled as both continuous variable (1-SD increment in log2-transformed adenine/creatinine ratio) and
700	categorical variable (low tertile as reference). There were 7 subjects in CRIC with missing values for the clinical co-
701	variates.
702	
703	
704	
705	
706	
707	
708	
709	
710	
711	
712	
713	
714	
715	
716	
717	
718	

719 Supplement Table 3. Correlations between urine adenine/creatinine ratio (UAdCR) and urine albumin/creatinine

ratio (UACR) or the estimated glomerular filtration rate (eGFR) in the non-macro groups from CRIC and SMART2D.

721	Cohort	UACP (r. p. valua)	oCEP (r. n. voluo)
	CRIC (n=551)	r=-0.02, p=0.62	r=0.01, p=0.74
	SMART2D (n=309)	r=0.01, <i>p</i> =0.82	r=-0.06, <i>p</i> =0.28
722			
723			
724			
725			
726			
727			
728			
729			
730			
731			
732			
733			
734			
735			
736			
737			
738			
739			
740			
741			
742			
743			
744			
745			

	ATIRMA (n=40)	KPMP (n=54)	CROCODILE (n=15)
Characteristics			
Age, years	24.3 ± 5.1	$(50.5 - 59.5) \pm 12.7$	24.1 ± 3.9
Sex			
Male, n (%)	20 (50.0)	22 (40)	7 (46.7)
Weight, kg	71.3 ± 12.6		73.5 ± 12.7
BMI, kg/m ²	24.1 ± 3.2		25.2 ± 3.9
HRT, n (%)		20 (36.4)	5 (33.3)
T1D, n (%)		4 (7.3)	8 (51.3)
T2D, n (%)		30 (56.4)	2 (13.3)
HbA1C (%)	7.8 ± 0.9		
MAP, mmHg	79.5 ± 7.4		
eGFR*, mL/min/1.73m ²	149.8 ± 33.9	(50.6 - 59.6) ± 23.6	148.8 ± 34.6
Urine ACR (mg/g)	10.35 ± 5.93		7.8 ± 7.9

746 Supplementary Table 4. Baseline characteristics of participants in ATIRMA, KPMP, and CROCODILE studies.

BMI: body-mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, MAP: mean arterial pressure, GFR: glomerular filtration rate, ERPF: estimated renal plasma flow, HbA1C: glycated hemoglobin A1c. (values expressed as Mean \pm SD)

Spatial Adenine	Correlation with Urine Adenine/Creatinine with Kidney Adenine by MALDI-MSI
Glom Adenine	R = 0.64, p<0.001
Non-Glom Adenine	R = 0.81, p<0.001
Whole Slide Image Adenine	R = 0.73, p<0.001

765 Supplementary Table 5. Correlation of urine adenine/creatinine ratio (UAdCR) with tissue levels of adenine.

766

767 Correlation of UAdCR measurements with tissue levels of adenine by spatial metabolomics of rat kidney samples

768 (n=9).

	db/m	db/m db/m + MTDIA		db/db + MTDIA
	(n=6)	(n=6)	(n=6)	(n=6)
Parameters				
Body weight	29.0 ±2.0	28.9 ±0.3	45.0 ±4.6	43.1 ±8.8
(g)				
Blood glucose	121.7 ±8.3	142.4 ±38.3	477.0 ±137.8	409.0 ± 150.8
(mg/dL)				
(g/mouse/day)	$4.6 \hspace{0.1 in} \pm 0.9$	5.4 ±1.7	5.8 ±0.6	5.5 ±1.1
Water intake				
(g/mouse/day)	4.3 ± 0.8	4.5 ±1.0	9.7 ±3.6	8.2 ±2.7

770 Supplementary Table 6. Clinical parameter in MTDIA treated db/db mice with type 2 diabets

Metabolites	db/db	db/db + MTDIA	
(mM/mg of protein)	$(\text{mean} \pm \text{SD})$	$(\text{mean} \pm \text{SD})$	
Alanine	210 ± 28.2	252 ±69.1	
Arginine	25 ± 5.6	29 ±9.9	
Asparagine	54 ± 12.9	64 ± 17.0	
Aspartic acid	188 ± 26.9	177 ±27.3	
Cysteine	88 ± 10.4	85 ±13.1	
Glutamic acid	584 ± 55.2	536 ± 59.6	
Glutamine	124 ± 14.5	124 ±31.4	
Glycine	472 ± 38.7	514 ±82.4	
Histidine	21 ±4.4	25 ±10.2	
Isoleucine	25 ±4.0	35 ±13.3	
Leucine	60 ± 10.0	81 ±30.9	
Lysine	35 ±9.0	46 ±19.3	
Methionine	25 ± 5.0	31 ±11.0	
Phenlyalanine	27 ±6.6	28 ± 8.2	
Proline	44 ±9.9	66 ±34.8	
Serine	96 ±21.3	125 ±48.4	
Threonine	56 ± 10.1	72 ±27.1	
Tryptophan	6 ±1.4	8 ±2.6	
Tyrosine	35 ± 7.0	47 ±17.8	
Valine	46 ±6.7	64 ±24.0	
3- hydroxykynurenine	N.D.	N.D.	
Betaine	118 ± 54.5	152 ±67.0	
DL-homocysteine	N.D.	N.D.	
GABA	3 ± 0.6	9 ±9.2	
Glycyl-histidine	0.13 ± 0.03	0.15 ±0.05	
Kynurenine	N.D.	N.D.	
L-a-aminobutyric acid	0.85 ± 0.77	0.62 ± 0.26	
Nicotinic acid	N.D.	N.D.	
Ornithine	5 ±1.7	11 ±7.6	
Pipecolate	0.66 ±0.21	$0.65\pm\!0.08$	
Serotonin	N.D.	N.D.	
Sulpiride	N.D.	N.D.	

789 Supplementary Table 7. Kidney metabolites in MTDIA treated db/db mice with type 2 diabets

790 791 792

The metabolites in the kidney were analyzed by ZipChip with LC-MS/MS.



794 Supplementary Figure 1. ZipChip urine adenine/creatinine assay correlates with LC-MS/MS. A ZipChip urine

adenine/creatinine assay was developed and found to highly correlate with urine adenine/creatinine measured by LC-

796 MS/MS. (n=23 samples, r=0.90, p<0.0001). Raw data was log-transformed and then normalized to urine creatinine.



....



Supplementary Figure 2. High urine adenine/creatinine ratio (UAdCR) levels identify patients with diabetes who are at high risk of ESKD and mortality (A) and ESKD (B) (combined CRIC and SMART2D). Participants with diabetes in the CRIC cohort and SMART2D cohorts had UAdCR levels measured within 1 year of enrollment and followed for 8-10 years. The top tertile had the highest risk of ESKD and all cause mortality (A) and ESKD alone (B).





834 Supplementary Figure 3. Urine adenine/creatinine ratio (UAdCR) levels are stable over time in Pima American

2nd adenine/creatine (nM/mg Creat)

835 Indians. Median time between measures of UAdCR is 12 months (IQR 11.8-12.5 months), R=0.665, p<0.0001, n=54

- 836 pairs).





845 Supplementary Figure 4. Hyperglycemia does not increase urine adenine/creatinine ratio (UAdCR) levels.

846 Patients with T1 diabetes underwent euglycemic clamp or hyperglycemic clamp with UAdCR measured at end of

- 847 clamp period (n=40 patients).
- 848
- 849
- 850
- 851
- 852
- _ _ _ _
- 853
- 854
- 855



Supplementary Figure 5. Adenine stimulates fibronectin, type I collagen and mTOR in human proximal tubular epithelial cells. Adenine administration to human kidney-2 (HK2) cells increases production of fibronectin and alpha2 chain of type I collagen (A) within 1h. Adenine stimulates mTOR activity within 5m of exposure as measured by phosphorylation of S6 kinase (B) (n=3 samples/group *p<0.05).



879

880 Supplementary Figure 6. Adenine stimulates kidney KIM-1 and kidney sTNFR1 levels. Adenine administration

881 to mice increases kidney levels of KIM-1 (A) and sTNFR1 (B). (n=12 in control group and n=7 in adenine treated

882 group, ****p<0.001).